Hypothermia as a cytoprotective strategy in ischemic tissue injury.
Hypothermia is a well established cytoprotectant, with remarkable and consistent effects demonstrated across multiple laboratories. At the clinical level, it has recently been shown to improve neurological outcome following cardiac arrest and neonatal hypoxia-ischemia. It is increasingly being embraced by the medical community, and could be considered an effective neuroprotectant. Conditions such as brain injury, hepatic encephalopathy and cardiopulmonary bypass seem to benefit from this intervention. It's role in direct myocardial protection is also being explored. A review of the literature has demonstrated that in order to appreciate the maximum benefits of hypothermia, cooling needs to begin soon after the insult, and maintained for relatively long period periods of time. In the case of ischemic stroke, cooling should ideally be applied in conjunction with the re-establishment of cerebral perfusion. Translating this to the clinical arena can be challenging, given the technical challenges of rapidly and stably cooling patients. This review will discuss the application of hypothermia especially as it pertains to its effects neurological outcome, cooling methods, and important parameters in optimizing hypothermic protection.
Tang
Xian N
XN
Department of Neurology, University of California, San Francisco, CA 94121, USA.
Yenari
Midori A
MA
D000818:Animals; D001930:Brain Injuries / Q000628:therapy; D002319:Cardiovascular System / Q000293:injuries; D019610:Cytoprotection / Q000502:physiology*; D006323:Heart Arrest / Q000628:therapy; D006501:Hepatic Encephalopathy / Q000628:therapy; D006801:Humans; D007036:Hypothermia, Induced / Q000379:methods*; D020925:Hypoxia-Ischemia, Brain / Q000628:therapy; D007231:Infant, Newborn; D007511:Ischemia / Q000628:therapy*; D051379:Mice; D051381:Rats; D013119:Spinal Cord Injuries / Q000628:therapy; D020521:Stroke / Q000628:therapy